reports
Conduit to Change Name to CDT Equity Inc.
Conduit to Change Name to CDT Equity Inc. Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying,...
Beneficient Appoints Tom Hicks as Chairman and James Silk as Interim C...
Beneficient Appoints Tom Hicks as Chairman and James Silk as Interim Chief Executive Officer DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced the separation of the roles of Chairman of the Board of Directors (“Board”) and Chief Executive Officer with the appointment of Thomas O. Hicks as Chairman of the Board and James ...
Beneficient Receives Nasdaq Listing Determination
Beneficient Receives Nasdaq Listing Determination Will Request Hearing DALLAS, July 18, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced that on July 16, 2025, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that, due to its continued non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rul...
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy Independent advisor appointed to assess feasibility and strategic benefit of a partial cryptocurrency-based treasury reserveInitiative aims to diversify capital positioning while retaining focus on IP-driven pharmaceutical development NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) (“Conduit” or the “Company”) today announced that it has engaged a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency tre...
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combinat...
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent f...
Beneficient Enters into $1.91 Million GP Primary Capital Transaction
Beneficient Enters into $1.91 Million GP Primary Capital Transaction DALLAS, June 24, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced it has closed on the financing of a $1.91 million primary capital commitment for Mendoza Ventures Growth Fund III, LP (“Fund”), a fund managed by Mendoza Ventures Growth GP III, L.L.C., LP (“Fund Manager...
Beneficient Announces Court Approval of GWG Litigation Settlement
Beneficient Announces Court Approval of GWG Litigation Settlement DALLAS, June 17, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today announced that the Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has approved the previously disclosed settlement agreement resolving all claims pending in the Bankruptc...
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoir...
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit’s pipeline while preserving full ownership of intellectual property and data, maxi...
Beneficient Adjourns Annual Meeting of Stockholders to 2 p.m. CDT May ...
Beneficient Adjourns Annual Meeting of Stockholders to 2 p.m. CDT May 29, 2025 DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which had been previously adjourned to 2:00 p.m. Central Daylight Time today, May 28, 2025, has been once again adjourned to al...
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s application to transf...
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance Conduit regains compliance with Bid Price and Equity RequirementsCDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with...
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on May 5, 2025. They granted the b...
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead ...
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Offic...
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904...
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces the filing of a new composi...
Beneficient Adjourns Annual Meeting of Stockholders
Beneficient Adjourns Annual Meeting of Stockholders DALLAS, April 30, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which had been previously adjourned to 9:00 a.m. Central time today, April 30, 2025, has been once again adjourned to allow for more time for stockholde...
Beneficient Enters into New GP Primary Capital Transaction
Beneficient Enters into New GP Primary Capital Transaction DALLAS, April 25, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced it has closed on the financing of a $233,333 primary capital commitment for Cork & Vines Fund I, LP (“Fund”), a fund managed by Cork & Vines GP, LP, an asset manager investing in opportunities within the premium ...
Beneficient Reminds Stockholders to Vote on Proxy Proposals Ahead of t...
Beneficient Reminds Stockholders to Vote on Proxy Proposals Ahead of the Company’s Annual Meeting on April 30, 2025 DALLAS, April 23, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben,” or the “Company”), a technology-enabled platform providing exit opportunities, primary capital solutions, and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, reminds stockholders to vote on proxy proposals before the upcoming Annual Meeting of Stockholders at 9:00 a.m. Central Time on April 30, 2025. Stockholder...
Beneficient Adjourns Annual Meeting of Stockholders
Beneficient Adjourns Annual Meeting of Stockholders DALLAS, April 16, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which had been previously adjourned to 9:00 a.m. Central time today, April 16, 2025, has been once again adjourned to allow for more time for stockholde...
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Announces Leadership Changes NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal...
Beneficient to Present at the Emerging Growth Conference on April 17, ...
Beneficient to Present at the Emerging Growth Conference on April 17, 2025 DALLAS, April 15, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, is pleased to announce that it will present a brief corporate update at the Emerging Growth Conference on Thursday, April 17, 2025. The Company will host a webcast group presentation at 4:10 PM Eastern Time. I...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.